Replies to post #247713 on Biotech Values

[DewDiligence]

ENTA insiders might not be able to buy shares now if the company is in partnership discussions regarding EDP-235.

Note that ENTA insiders—and especially CEO Jay Luly—are large stockholders who own, respectively, 12.7% and 6.8% of ENTA’s shares outstanding—see p.6 at https://www.sec.gov/Archives/edgar/data/1177648/000119312523011979/d398448ddef14a.htm#toc398448_3 .

[Jake2234]

Bewildered is an understatement

[vinmantoo]

Rwwine, I am never surprised at shortsightedness and fear driving a stock down, or for that matter the stock market.
Most Biotech stocks took a beating today. Did they all have bad news? Obviously not.

I have a lot of confidence in ENTA given how impressive the EDP-235 phase 2 trial data was.